AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01655875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
Study NCT06609993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secondary treatment of postoperative nausea and vomiting (PONV)
Description: Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously when incidence of persistent PONV is observed despite the dexamethasone in a dose of 4 mg will be administration intravenously
Study NCT02008656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (OXAL)
Study NCT02008656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Study NCT02008656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT02008656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda®)
Study NCT02008656 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiotherapy (IMRT)
Study NCT02008656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Study NCT02008656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DRE-Endoscopy
Study NCT00667264 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineural ropivacaine
Description: Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
Study NCT00667264 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: perineural ropivacaine
Description: Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
Study NCT00723827 — intervention group
Intervention type: DRUG
Intervention: Temozolomide
Description: Administration of temozolomide based on the product labeling.
Study NCT00723827 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
Study NCT00839124 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Center Reference Endotoxin (CCRE)
Description: inhalation challenge with 20,000 EU CCRE
Study NCT00839124 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Center Reference Endotoxin (CCRE)
Description: inhalation of 20,000 EU CCRE
Study NCT01429090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling
Description: blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
Study NCT01429090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
Study NCT01429090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vagantin®
Description: administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
Study NCT01429090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methantheline solution
Description: administration 100 ml methantheline solution (100 mg methantheline bromide)
Study NCT01429090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of salivation
Description: Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing
Study NCT01429090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of salivation
Description: Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing
Study NCT01429090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of accommodation
Description: Accommodation was measured with the optometer according to Schober (Velhagen 1972)
Study NCT01429090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of accommodation
Description: Accommodation was measured with the optometer according to Schober (Velhagen 1972)
Study NCT01429090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pupillometry
Description: Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
Study NCT01429090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
Study NCT03686592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of body awareness
Description: Questionnaires+ interviews
Study NCT03686592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of body awareness
Description: Questionnaires+ interviews
Study NCT04573660 — intervention group
Intervention type: DEVICE
Intervention: Coronary and peripheral stents
Description: The participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
Study NCT04573660 — intervention group
Intervention type: DEVICE
Intervention: Pacing catheters
Description: The participants in the Pacing catheters arm will receive Pacing catheters
Study NCT04573660 — intervention group
Intervention type: DEVICE
Intervention: Vascular plugs
Description: The participants in the Vascular plugs arm will receive Vascular plugs
Study NCT04573660 — intervention group
Intervention type: DEVICE
Intervention: Measurement and imaging (FFR and OCT)
Description: The participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
Study NCT04573660 — intervention group
Intervention type: DEVICE
Intervention: Peripheral dilatation catheters
Description: The participants in the Peripheral dilatation catheters will receive Peripheral dilatation catheters
Study NCT04573660 — intervention group
Intervention type: DEVICE
Intervention: Coronary dilatation catheters
Description: The participants in the Coronary dilatation catheters will receive Coronary dilatation catheters
Study NCT04573660 — intervention group
Intervention type: DEVICE
Intervention: Coronary and peripheral guidewires
Description: The participants in the Coronary and peripheral guidewires will receive Coronary and peripheral guidewires
Study NCT04573660 — intervention group
Intervention type: DEVICE
Intervention: Vessel closure/compression devices
Description: The participants in the Vessel closure/compression devices will receive Vessel closure/compression devices
Study NCT04573660 — intervention group
Intervention type: DEVICE
Intervention: Vascular access introducers
Description: The participants in the Vascular access introducers arm will receive Vascular access introducers
Study NCT02215902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Affinity plasmapheresis
Description: Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
Study NCT04496232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICSI
Description: Semen processing by density gradient centrifugation followed by sperm selection by PICSI dishes of the first ejaculate
Study NCT04496232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Second ejaculate
Description: Semen processing by density gradient centrifugation for the second ejaculate
Study NCT03362944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Music Therapy
Description: The intervention consists of a standardized series of Music Therapy tasks, all based at a constant rhythmic pulse.
Study NCT03362944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive Music Therapy
Description: The intervention consists of a series of recorded listening tracks, matched in style to the active intervention, all based at a constant rhythmic pulse.
Study NCT02968810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT02968810 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT02968810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02968810 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02968810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02968810 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02968810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT02968810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02968810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02968810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Given PO
Study NCT03758729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
Study NCT03758729 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy
Study NCT05452265 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic resection
Description: Complete resection of gastric SETs was recommended if the tumor size was >2 cm, presence of malignant features, or if the patient was symptomatic, declined periodical surveillance, and preferred to undergo diagnostic and therapeutic resection.
Study NCT00821535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: maraviroc (Selzentry, Celsentri)
Description: 12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
Study NCT01079780 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Given IV
Study NCT01079780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT01079780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Given IV
Study NCT01079780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01079780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT03468504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Participants view the reflective side of a simple mirror which is placed in their mid-sagittal plane to view a mirror reflection of their non-affected limb for 30 mins per day, 3 days per week, for four weeks.
Study NCT03468504 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mirror Therapy
Description: Placebo Mirror Therapy: Participants view the reflective side of a simple mirror which is placed forward/ahead of them in their mid-sagittal plane, and thus cannot see a reflection of either lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
Study NCT03468504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
Study NCT03468504 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill
Description: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
Study NCT04325997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngoscope with mouth opener
Description: Double-lumen tube combined with mouth gag for laryngoscope intubation
Study NCT04325997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope with mouth opener
Description: Double-lumen tube combined with mouth gag for video laryngoscope intubation
Study NCT01565863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Goal Attainment Program
Description: The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
Study NCT00853762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 25 mg
Description: Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Study NCT00853762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Description: Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Study NCT00853762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Study NCT00853762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Study NCT01873014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chinese herbs-I
Description: two agent per day, twice a day
Study NCT01873014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chinese herbs-II
Description: two agent per day, twice a day
Study NCT04568655 — intervention group
Intervention type: DEVICE
Intervention: noninvasive ventilation
Description: noninvasive ventilation to support the COVID-19 patients with respiratory failure
Study NCT03181308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carotuximab (TRC105)
Description: Anti Endoglin Antibody
Study NCT03181308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPDIVO
Description: Programmed Death Receptor-1
Study NCT00597259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys plus Entecavir
Description: Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
Study NCT00597259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: ETV 0.5 mg daily monotherapy for 144 weeks
Study NCT03986099 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring virus load
Description: Near point of care
Study NCT00687934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Description: This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
Study NCT00906243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV9103
Description: CV9103 encodes for 4 prostate specific antigens.
Study NCT03541993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Study NCT03541993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01663623 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01663623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg
Study NCT01663623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine
Study NCT01663623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine
Study NCT00560716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC116
Description: Dose escalation of CYC116
Study NCT02251275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
Study NCT01548963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive glycemia control
Description: Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
Study NCT01548963 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive glycemia control
Description: Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
Study NCT03836586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Intervention
Description: This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
Study NCT03836586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Education
Description: General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
Study NCT02817139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS
Study NCT02817139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TDCS
Study NCT02817139 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TDCS
Study NCT04147156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epley's Maneuver
Description: Treatment with Epley's Maneuver in the ROTUNDUM-chair
Study NCT04147156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Semont Maneuver
Description: Treatment with the Semont Maneuver in the ROTUNDUM-chair
Study NCT04147156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 360 degree vertical rotation
Description: Treatment with 360 degree vertical rotation in the ROTUNDUM-chair
Study NCT01868568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin).
Study NCT06609993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraopertative fluid challenge (IFC)
Description: 3 mililitre of synthetic colloid will be transfused intravenously per each sudden blood loss of 1 mililitre
Study NCT06609993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: postoperative rescue opioid analgesia using morphine
Description: postoperative rescue opioid analgesia will be administered intravenously using 2 miligrams of morphine ((Morfini Sulfas WZF, 20mg/ml, solutio pro iniectione, Polfa Warszawa, Poland)every 10 minutes until postoperative pain perception using NPRS scale will decrease below 4 (NPRS; 0 meant no pain and 10 meant the worst pain imaginable)
Study NCT01868568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 30
Description: A single dose administered subcutaneously (s.c., under the skin).